Brief: Paratek Pharmaceuticals Reports Full Year 2020 Total Rev Of $46.9 Mln
24/02/2021 21:31
Feb 24 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES FULL YEAR 2020 TOTAL
REVENUE
OF $46.9 MILLION INCLUDING NUZYRA® (OMADACYCLINE) NET U.S. SALES
OF $38.8 MILLION
* Q4 REVENUE ROSE 17 PERCENT TO $16 MILLION
* Q4 REVENUE ESTIMATE $43.6 MILLION -- REFINITIV IBES DATA
* EXPECTS FULL YEAR 2021 TOTAL REVENUE BETWEEN $166 AND $177
MILLION
* FY2021 REVENUE VIEW $182.8 MILLION -- REFINITIV IBES DATA
* Q4 LOSS PER SHARE $0.54
* Q4 EARNINGS PER SHARE VIEW $-0.05 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNXbfnStL
Further company coverage: PRTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million